Log In
Print this Print this

ExoIntelliScore Prostate, Prostate cancer liquid biopsy test (formerly Exo106)

  Manage Alerts
Collapse Summary General Information
Company Exosome Diagnostics Inc.
DescriptionNon-invasive, urine-based liquid biopsy prostate cancer test that analyzes the expression of 3 biomarkers utilizing exosomal RNA to determine a predictive risk score (EXO106 Score)
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPivotal
Standard IndicationCancer, Diagnostic
Indication DetailsDetect high-grade prostate cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today